COVID-19 INFORMATION AND RESOURCES

Your Health
man_lab_dark_790x500.jpg
man_lab_dark_1000x450.jpg

COVID-19 INFORMATION AND RESOURCES

Current information on our scientific progress to bring forward a safe and effective vaccine to help protect against the novel coronavirus.

FOUR WAYS TO REMAIN VIGILANT ABOUT COVID-19

Your Health
COVID-19_July_4_380x500.jpg
COVID-19_July_4_1000x450_0.jpg

FOUR WAYS TO REMAIN VIGILANT ABOUT COVID-19

How you can keep yourself and your family safe this summer and minimize the spread of the coronavirus.

Perspectives on COVID-19 from Mace Rothenberg, M.D.

Your Health
mace_2019_380x500_1.png
mace_2019_1000x450.jpg

Perspectives on COVID-19 from Mace Rothenberg, M.D.

Mace Rothenberg, M.D., Pfizer’s CMO shares some tips about new information and research when it comes to COVID-19.

PARTNERING WITH DIRECT RELIEF TO PROVIDE COVID-19 SUPPLIES TO HOSPITALS

Our Purpose
DSC07402_790x500.png
DSC07402_1000x450.jpg

PARTNERING WITH DIRECT RELIEF TO PROVIDE COVID-19 SUPPLIES TO HOSPITALS

We have always been committed to deploying our resources in times of crisis, and we leveraged our long-standing partnership with Direct Relief to help alleviate issues facing hospitals.

Find a Trial

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

MANUFACTURING AND GLOBAL SUPPLY CAPABILITIES

News
PGS_COVID_FIH_380x700.png
PGS_COVID_FIH_1000x450.png

MANUFACTURING AND GLOBAL SUPPLY CAPABILITIES

How we are scaling up to manufacture and supply a COVID-19 vaccine, if approved.

Age: Addressing a Blind Spot in Cancer Care

Our Purpose
Health Equity Article_790x500_0.png
Health Equity Article_1000x450_0.jpg

Age: Addressing a Blind Spot in Cancer Care

At Pfizer, we're focused on removing barriers for all people living with cancer - including those over the age of 65 - to address disparities in cancer care and improve health equity.

Latest News

Supply of 120 million doses to be provided in the first half of 2021, subject to regulatory approval Agreement is part of Pfizer’s and BioNTech’s global commitment to help address the pandemic Pfizer and BioNTech began a Phase 2b/3 safety and efficacy trial and remain on track to seek regulatory review as early as October 2020, and manufacture globally up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021 Pfizer Inc. (NYSE: PFE) and BioNTech SE (…